Viridian Therapeutics, Inc.\DE (VRDN) Notes Payables (2013 - 2020)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Notes Payables of $4.7 million for Q3 2020, up 18.5% year-over-year from $4.0 million in Q4 2019, and up 37.75% quarter-over-quarter from $3.4 million in Q2 2020.
Viridian Therapeutics, Inc.\DE (VRDN) Notes Payables (2013 - 2020) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Notes Payables history runs 8 years deep, the most recent figure standing at $4.7 million for Q3 2020.
- In Q3 2020, Notes Payables rose 18.5% year-over-year to $4.7 million; the TTM figure through Sep 2020 stood at $4.7 million (up 18.5% YoY), while the FY2019 annual figure was $4.0 million, up 73.32% from the prior year.
- Notes Payables for Q3 2020 stood at $4.7 million, up from $3.4 million in the prior quarter.
- The five-year high for Notes Payables was $4.7 million in Q3 2020, with the low at $289000.0 in Q2 2018.
- The 5-year median for Notes Payables is $2.0 million (2017), against an average of $2.5 million.
- The sharpest annual moves came in 2018 and 2019: Notes Payables sank 85.4% in 2018, then surged 1273.7% in 2019.
- Viridian Therapeutics, Inc.\DE's Notes Payables stood at $2.0 million in 2016, then grew by 0.71% to $2.0 million in 2017, then climbed by 15.68% to $2.3 million in 2018, then soared by 73.32% to $4.0 million in 2019, then rose by 18.39% to $4.7 million in 2020.
- Business Quant data shows VRDN's Notes Payables at $4.7 million in Q3 2020, $3.4 million in Q2 2020, and $4.0 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 4.71 Mn |
| Jun 30, 2020 | 3.42 Mn |
| Mar 31, 2020 | 3.98 Mn |
| Dec 31, 2019 | 3.98 Mn |
| Sep 30, 2019 | 3.97 Mn |
| Jun 30, 2019 | 3.97 Mn |
| Mar 31, 2019 | 3.30 Mn |
| Dec 31, 2018 | 2.29 Mn |
| Sep 30, 2018 | 1.29 Mn |
| Jun 30, 2018 | 289,000.00 |
| Sep 30, 2017 | 1.98 Mn |
| Jun 30, 2017 | 1.98 Mn |
| Mar 31, 2017 | 1.97 Mn |
| Dec 31, 2016 | 1.97 Mn |
| Sep 30, 2016 | 1.11 Mn |
| Jun 30, 2016 | 1.11 Mn |
| Mar 31, 2016 | 1.11 Mn |
| Dec 31, 2015 | 1.11 Mn |
| Sep 30, 2015 | 1.11 Mn |
| Jun 30, 2015 | 1.11 Mn |